Figure 7.

Evaluation of the CDKN2A index in pre-treatment cfDNA improves risk stratification and prediction of NMIBC progression to muscle-invasive disease

(A and B) Kaplan-Meier survival curves for the PFS of NMIBC patients according to CDKN2A index in pre-treatment cfDNA combined with tumor stage/grade (A) and EORTC risk group (B). The p values were calculated by log rank test. (C) DCA curves of “cfDNA CDKN2A index-fitted” and “control” multivariate prognostic models for the PFS of NMIBC patients. Net benefit is plotted against various ranges of threshold probabilities.